Endomyocardial Biopsy Market (2025 - 2030) Size, Share & Trends Analysis Report By Product (Forceps, Accessories), By Tip (Straight, Pre-curved), By End-use (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts

Endomyocardial Biopsy Market Size & Trends

The global endomyocardial biopsy market size was estimated at USD 365.3 million in 2024 and is expected to grow at a CAGR of 6.9% from 2025 to 2030. The growth of the market is being driven by various factors such as the increasing prevalence of cardiovascular diseases, developments in diagnostic technologies, increasing geriatric population, and growing research and development activities. The sedentary lifestyle by the majority of the population has driven the prevalence of various types of CVDs globally.

Physical inactivity, smoking, high blood pressure, and obesity are some of the major factors boosting the CVD rate. For instance, according to CDC, more than 60% of adults in the U.S. do not engage in recommended physical activity, whereas around 25% of adults are not active at all. In addition, it was estimated that around 30.8 million people in the U.S. alone smoke cigarettes, whereas 16 million Americans are anticipated to be living with smoking-related disorders.

Furthermore, the increasing number of heart transplants has boosted the demand for EMB procedures. Endomyocardial biopsy remains a valuable diagnostic tool for assessing graft function & detecting rejection in heart transplant patients, and it is likely to continue to be used as part of routine post-transplant. According to the data published by the United Network for Organ Sharing, in 2021, approximately 31,238 transplants have been performed at hospitals across the country in the last 10 years, and the number has been significantly increasing.

Product Insights

The forceps segment led the market and accounted for the largest revenue share, 71.9%, in 2024. Forceps are commonly used to perform Endomyocardial Biopsy (EMB) procedures. They are now available in a range of shapes & sizes to suit the needs of different patients and procedures. Companies such as Argon Medical Devices, Inc. and Cordis, among others, offer a range of forceps that could be used during biopsy procedures.

The accessories segment is anticipated to grow at a lucrative CAGR of 6.3% growth over the forecast period. Several other accessories that are commonly used in EMB procedures are guidewires, biopsy needles, curve tips, and catheters. The choice of an accessory depends on the specific needs of the procedure and the patient's analysis. Furthermore, advancements in EMB accessories, such as flexible needles, and improved imaging tools, have also contributed to the market growth.

Tip Insights

The straight tip segment dominated the global endomyocardial biopsy market and held the largest revenue share of 36.2% in 2024. The straight tip is designed to allow precision and accuracy during the procedure. The use of a straight tip minimizes the risk of tissue damage during the biopsy, ensuring that the collected tissue is suitable for accurate diagnosis. The straight tip is commonly used for initial puncture and navigation through the heart, allowing for the collection of a tissue sample. Thus, these factors are expected to further drive the segment growth.

The pre-curved segment is expected to expand at a substantial CAGR of 7.3% over the forecast period. The pre-curved tip provides flexibility during the procedure, reducing the risk of damage to surrounding tissues. These factors are expected to further boost the adoption of pre-curved tips during the forecast period.

End Use Insights

Hospitals held the dominant position in the global market, with the largest revenue share of 51.5% in 2024. Factors such as increasing the number of transplants would further increase the volume of procedures performed in the hospitals, thereby generating additional revenue from diagnostic tests and follow-up care, which would further improve patient outcomes. Furthermore, the rising number of hospitals globally is expected to fuel market growth, as more people will have access to healthcare services.

The ambulatory surgery center (ASC) is anticipated to exhibit a significant CAGR of 6.0% over the forecast period. ASCs are majorly preferred by the patients who prefer a more convenient and cost-effective alternative to hospital-based procedures. In addition, with the continuous advancements in technology, EMB procedures can now be safely and effectively performed in an ASC setting, reducing the need for hospitalization.

Regional Insights

The North America endomyocardial biopsy market dominated the global market and held the largest revenue share of 43.0% in 2024. The region has a well-established healthcare infrastructure and a large patient pool with a high prevalence of cardiovascular diseases, which makes it an attractive market for EMB procedures. In addition, the presence of key market players is also contributing to the growth of the market by investing in R&D, introducing innovative products, and providing advanced training and education to healthcare providers.

U.S. Endomyocardial Biopsy Market Trends

The endomyocardial biopsy market in the U.S. dominated the North American market with the largest revenue share in 2024, attributed to the rising incidences of heart transplants and increasing prevalence of myocarditis and cardiomyopathy. In addition, expanding healthcare infrastructure and growing awareness among cardiologists continue to boost procedural volumes. Furthermore, advancements in biopsy techniques also support clinical adoption, while government funding and insurance coverage promote patient access.

Asia Pacific Endomyocardial Biopsy Market Trends

The Asia Pacific endomyocardial biopsy market is projected to grow at the fastest CAGR of 10.0% over the forecast period. The market's growth is attributed to factors such as increasing awareness about heart diseases and the need for early diagnosis and treatment. Furthermore, improving healthcare infrastructure in the region has boosted the availability of endomyocardial biopsy services.

The endomyocardial biopsy market in China led the Asia Pacific market and held the largest revenue share in 2024, driven by strong growth due to rapid urbanization and lifestyle changes leading to a surge in cardiovascular diseases. Furthermore, increasing investment in advanced diagnostic tools is bridging the technology gap, while rising healthcare spending enables broader patient reach.

Europe Endomyocardial Biopsy Market Trends

The European endomyocardial biopsy market is expected to grow significantly over the forecast period due to the rising cardiovascular disease burden aligned with increased emphasis on early diagnosis. Integration of biopsy procedures into standardized care pathways encourages consistent clinical usage. In addition, supportive regulatory frameworks and collaborative research across member countries help accelerate technological uptake.

Key Endomyocardial Biopsy Company Insights

The endomyocardial biopsy market is consolidated and has major key players such as Argon Medica Devices, Inc., Cordis, Mermaid Medical, Terumo Corporation, Scholten Surgical Instruments, Inc., Changzhou Lookmed Medical Instrument Co., Ltd., and Fehling Instruments. These players focus on growth strategies, such as new product launches, collaborations, partnerships, expansion, and mergers and acquisitions.

• Argon Medical Devices specializes in interventional medical devices, focusing on areas such as interventional radiology, vascular surgery, interventional cardiology, and interventional oncology. 

• Terumo Corporation operates in the cardiovascular medical device sector, offering products for cardiac and vascular surgeries. Terumo's products are utilized in various cardiovascular procedures, aiming to improve patient safety and surgical outcomes.

Endomyocardial Biopsy Market Report Scope

Global Endomyocardial Biopsy Market Report Segmentation

This report forecasts revenue growth at global, regional and country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global endomyocardial biopsy market report based on product, tip, end use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Forceps

  • Accessories

• Tip Outlook (Revenue, USD Million, 2018 - 2030)

  • Maxi-curved

  • Straight

  • Precurved

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Ambulatory Surgical Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait